Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Enzyre B.V. logo — Breakthrough ambulant diagnostic and monitoring technology f...

Enzyre B.V.

Breakthrough ambulant diagnostic and monitoring technology for coagulation testing

Founded 2016 The Netherlands The Netherlands 12 employees Series A Total: $13.40M Health Care, Medical Devices

General Information

Company Name Enzyre B.V.
Founded Year 2016
Location The Netherlands The Netherlands +1
Founders / Decision Makers
Team member
Employees 12
Industries Health Care, Medical Devices
Funding Stage Series A
Social

Get notified when Enzyre B.V. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Sep 07, 2026

Enzyre B.V. highlights its collaboration with Self-screen B.V. on developing a simplified DNA methylation test for cervical cancer screening on a Lab-on-Chip.

Program Acceptance Sep 07, 2026

Enzyre B.V. is participating in the NXTGEN Hightech Biomed02 (Lab-on-Chip) program, collaborating with various experts to advance Lab-on-Chip diagnostics.

Get alerts when Enzyre B.V. shows new signals

About Enzyre B.V.

Enzyre B.V., a pioneering player in the Health Care and Medical Devices sectors, is emerging from the landscape of innovative startups with its focus on transformative diagnostics technology. Launched as a spin-off from UMC St. Radboud in March 2017, Enzyre is on a mission to revolutionize personalized medicine through its innovative solutions.

The company is centered around creating a point of care (POC) diagnostic platform using chemiluminescence to measure multiple enzymatic reactions. Its slogan, "Breakthrough ambulant diagnostic technology for coagulation testing," succinctly captures its disruptive vision.

Headquartered in The Netherlands, Enzyre garnered substantial interest with a €12.00M Series A investment on 02 November 2022, led by investors such as Oost NL, Takeda Pharma, Novalis Biotech, Demcon, and i&i Biotech Fund. This financial backing positions Enzyre to further its pioneering advancements in diagnostics.

Taxonomy: ambulant diagnostic technology, coagulation testing, Enzyre, UMC St. Radboud, spin-off company, personalized medicine, point of care, POC diagnostic platform, chemiluminescence, diagnostic technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 5
Investor Investor Investor
•••• •••• 		02 Nov 2022
Debt Financing •••••• 1
Investor
27 Jul 2020

Enzyre B.V. Alternatives & Competitors

Enzyre B.V. vs
Heliks R&D and Biotechnology Inc.
Heliks R&D and Biotechnology Inc. Turkey

Diagnostic and research kits suitable for every laboratory.

9 employees
Enzyre B.V. vs
Thrixen
Thrixen Singapore

Unlocking the next generation of simple, affordable & accessible diagnostics

Series Unknown
10 employees
Biotechnology, Health Care
Enzyre B.V. vs
Beijing Chemclin Biotech Co., Ltd.
Beijing Chemclin Biotech Co., Ltd.

Beijing Chemclin Biotech Co., Ltd. ("Chemclin"), a fully-owned subsidiary company of China Diagnosti...

Private Equity
22 employees
Biotechnology, Health Care

FAQ About Enzyre B.V.

Breakthrough ambulant diagnostic and monitoring technology for coagulation testing
Enzyre B.V. was founded in 2016.
Enzyre B.V. is headquartered in The Netherlands.
Enzyre B.V. operates in the following industries: Health Care, Medical Devices.
Enzyre B.V. has approximately 12 employees.
Enzyre B.V. has completed 2 funding rounds, raising a total of $13.40M. The latest funding stage is Series A.
Top alternatives and competitors to Enzyre B.V. include Heliks R&D and Biotechnology Inc., Thrixen, Beijing Chemclin Biotech Co., Ltd., Eurolab medical devices, ALiA BioTech . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enzyre B.V. and Heliks R&D and Biotechnology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Enzyre B.V. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes